Literature DB >> 12020966

Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: association with clinical and MRI activity.

Niels Hellings1, Geert Gelin, Robert Medaer, Liesbeth Bruckers, Yvan Palmers, Jef Raus, Piet Stinissen.   

Abstract

In multiple sclerosis (MS), T-cells are considered to be critical in coordinating an immunopathological cascade that results in myelin damage. We investigated whether clinical disease activity or brain inflammatory activity as measured by magnetic resonance imaging (MRI) was associated with changes in autoreactive T-cell reactivities in MS patients. To this end, a longitudinal study was performed in which T-cell-related immune parameters and clinical parameters (including MRI) were monitored in seven relapsing-remitting (RR) MS patients and two healthy controls with bimonthly intervals over a period of 18 months. The serial evaluation of antimyelin (MBP, PLP, MOG) T-cell responses revealed highly dynamic shifts and fluctuations from one pattern to another in a patient-dependent manner. In some of the patients, changes in T-cell-related immune variables were found to concur with MRI activity and generally preceded clinical relapses. These alterations include: increased number of myelin-reactive IFN-gamma secreting T-cells, detection of clonally expanded myelin-reactive T-cells, elevated proinflammatory and decreased antiinflammatory cytokine production, upregulation of ICAM-1 membrane expression and highly increased serum levels of soluble VCAM-1. However, not all exacerbations and MRI changes were associated with changes in antimyelin reactivity. Some of the observed immune alterations were also detected in the healthy controls, indicating that additional regulatory mechanisms-which may be defective in MS-play a role in the downregulation of potentially pathological T-cell responses. In conclusion, this study provides further support for an important role of myelin-reactive T-cells in the pathogenesis of MS. In addition, the observed dynamic changes in the antimyelin T-cell reactivity pattern may be a major obstacle for the development of antigen-specific immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12020966     DOI: 10.1016/s0165-5728(02)00052-8

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

1.  Skewed autoantibody reactivity to the extracellular domain of myelin oligodendrocyte glycoprotein in multiple sclerosis.

Authors:  Maria V Tejada-Simon; Jian Hong; Victor M Rivera; Jingwu Z Zhang
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

Review 2.  Stage-specific immune dysregulation in multiple sclerosis.

Authors:  Benjamin M Segal
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

3.  Immunopathology of Japanese macaque encephalomyelitis is similar to multiple sclerosis.

Authors:  Tiffany C Blair; Minsha Manoharan; Stephanie D Rawlings-Rhea; Ian Tagge; Steven G Kohama; Julie Hollister-Smith; Betsy Ferguson; Randall L Woltjer; Meredith C Frederick; James Pollaro; William D Rooney; Larry S Sherman; Dennis N Bourdette; Scott W Wong
Journal:  J Neuroimmunol       Date:  2015-12-02       Impact factor: 3.478

Review 4.  CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies.

Authors:  A Arévalo-Martín; D García-Ovejero; O Gómez; A Rubio-Araiz; B Navarro-Galve; C Guaza; E Molina-Holgado; F Molina-Holgado
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

5.  T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study.

Authors:  A Van der Aa; N Hellings; R Medaer; G Gelin; Y Palmers; J Raus; P Stinissen
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

6.  Human platelet antigen (HPA)-1a peptides do not reliably suppress anti-HPA-1a responses using a humanized severe combined immunodeficiency (SCID) mouse model.

Authors:  D J Jackson; J L Eastlake; B M Kumpel
Journal:  Clin Exp Immunol       Date:  2014-04       Impact factor: 4.330

7.  VCAM-1-targeted magnetic resonance imaging reveals subclinical disease in a mouse model of multiple sclerosis.

Authors:  Sébastien Serres; Silvy Mardiguian; Sandra J Campbell; Martina A McAteer; Asim Akhtar; Alexandre Krapitchev; Robin P Choudhury; Daniel C Anthony; Nicola R Sibson
Journal:  FASEB J       Date:  2011-09-09       Impact factor: 5.191

8.  The Worm-Specific Immune Response in Multiple Sclerosis Patients Receiving Controlled Trichuris suis Ova Immunotherapy.

Authors:  Ivet A Yordanova; Friederike Ebner; Axel Ronald Schulz; Svenja Steinfelder; Berit Rosche; Anna Bolze; Friedemann Paul; Henrik E Mei; Susanne Hartmann
Journal:  Life (Basel)       Date:  2021-01-29

9.  Expression of scavenger receptor A on antigen presenting cells is important for CD4+ T-cells proliferation in EAE mouse model.

Authors:  Hilit Levy-Barazany; Dan Frenkel
Journal:  J Neuroinflammation       Date:  2012-06-07       Impact factor: 8.322

Review 10.  Autoimmune T-cell reactivity to myelin proteolipids and glycolipids in multiple sclerosis.

Authors:  Judith M Greer
Journal:  Mult Scler Int       Date:  2013-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.